These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


181 related items for PubMed ID: 24467480

  • 1. Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study.
    Amiot A, Lévy M, Copie-Bergman C, Dupuis J, Szablewski V, Le Baleur Y, Baia M, Belhadj K, Sobhani I, Leroy K, Haioun C, Delchier JC.
    Aliment Pharmacol Ther; 2014 Mar; 39(6):619-28. PubMed ID: 24467480
    [Abstract] [Full Text] [Related]

  • 2. Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study.
    Lévy M, Copie-Bergman C, Amiot A, Dupuis J, Le Baleur Y, Belhadj K, Hémery F, Sobhani I, Delfau-Larue MH, Leroy K, Haioun C, Delchier JC.
    Leuk Lymphoma; 2013 May; 54(5):940-4. PubMed ID: 22978684
    [Abstract] [Full Text] [Related]

  • 3. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
    Li X, Xia B, Guo S, Zhan Z, Zhang L, Zhao D, Wu X, Zhang Y.
    Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
    [Abstract] [Full Text] [Related]

  • 4. Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome.
    Levy M, Copie-Bergman C, Traulle C, Lavergne-Slove A, Brousse N, Flejou JF, de Mascarel A, Hemery F, Gaulard P, Delchier JC, Groupe d'Etude des Lymphomes de l'Adulte (GELA).
    Am J Gastroenterol; 2002 Feb; 97(2):292-7. PubMed ID: 11866264
    [Abstract] [Full Text] [Related]

  • 5. Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment.
    Nakamura S, Matsumoto T, Suekane H, Nakamura S, Matsumoto H, Esaki M, Yao T, Iida M.
    Cancer; 2005 Aug 01; 104(3):532-40. PubMed ID: 15937928
    [Abstract] [Full Text] [Related]

  • 6. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.
    Aguiar-Bujanda D, Llorca-Mártinez I, Rivero-Vera JC, Blanco-Sánchez MJ, Jiménez-Gallego P, Mori-De Santiago M, Limeres-Gonzalez MA, Cabrera-Marrero JC, Hernández-Sosa M, Galván-Ruíz S, Hernández-Sarmiento S, Saura Grau S, Bohn-Sarmiento U.
    Hematol Oncol; 2014 Sep 01; 32(3):139-44. PubMed ID: 24123108
    [Abstract] [Full Text] [Related]

  • 7. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan.
    Nakamura S, Sugiyama T, Matsumoto T, Iijima K, Ono S, Tajika M, Tari A, Kitadai Y, Matsumoto H, Nagaya T, Kamoshida T, Watanabe N, Chiba T, Origasa H, Asaka M, JAPAN GAST Study Group.
    Gut; 2012 Apr 01; 61(4):507-13. PubMed ID: 21890816
    [Abstract] [Full Text] [Related]

  • 8. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma.
    Chen LT, Lin JT, Tai JJ, Chen GH, Yeh HZ, Yang SS, Wang HP, Kuo SH, Sheu BS, Jan CM, Wang WM, Wang TE, Wu CW, Chen CL, Su IJ, Whang-Peng J, Cheng AL.
    J Natl Cancer Inst; 2005 Sep 21; 97(18):1345-53. PubMed ID: 16174856
    [Abstract] [Full Text] [Related]

  • 9. Successful treatment of Helicobacter pylori-negative gastric MALT lymphoma with rituximab.
    Chaudhary N, Ozer H, Huard D, Lightfoot S, Mesiya S.
    Dig Dis Sci; 2006 Apr 21; 51(4):775-8. PubMed ID: 16615002
    [Abstract] [Full Text] [Related]

  • 10. Mucosal change of the stomach with low-grade mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: follow-up study of 48 cases.
    Begum S, Sano T, Endo H, Kawamata H, Urakami Y.
    J Med Invest; 2000 Feb 21; 47(1-2):36-46. PubMed ID: 10740978
    [Abstract] [Full Text] [Related]

  • 11. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection.
    Morgner A, Miehlke S, Fischbach W, Schmitt W, Müller-Hermelink H, Greiner A, Thiede C, Schetelig J, Neubauer A, Stolte M, Ehninger G, Bayerdörffer E.
    J Clin Oncol; 2001 Apr 01; 19(7):2041-8. PubMed ID: 11283137
    [Abstract] [Full Text] [Related]

  • 12. Rituximab or rituximab plus chlorambucil for translocation (11;18)-negative gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomized observational study.
    Lévy M, Dupuis J, Charpy C, Martin A, Itti E, Sobhani I, Haioun C, Amiot A.
    Leuk Lymphoma; 2022 Nov 01; 63(11):2597-2603. PubMed ID: 35687839
    [Abstract] [Full Text] [Related]

  • 13. Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up.
    Lévy M, Copie-Bergman C, Molinier-Frenkel V, Riou A, Haioun C, Gaulard P, Delfau-Larue MH, Sobhani I, Leroy K, Delchier JC.
    Leuk Lymphoma; 2010 Feb 01; 51(2):284-90. PubMed ID: 20038225
    [Abstract] [Full Text] [Related]

  • 14. A prospective analysis of low-grade gastric malt lymphoma after Helicobacter pylori eradication.
    Hong SS, Jung HY, Choi KD, Song HJ, Lee GH, Oh TH, Jo JY, Kim KJ, Byeon JS, Myung SJ, Yang SK, Hong WS, Kim JH, Min YI.
    Helicobacter; 2006 Dec 01; 11(6):569-73. PubMed ID: 17083379
    [Abstract] [Full Text] [Related]

  • 15. Clinical features and prognosis of gastric MALT lymphoma with special reference to responsiveness to H. pylori eradication and API2-MALT1 status.
    Nakamura T, Seto M, Tajika M, Kawai H, Yokoi T, Yatabe Y, Nakamura S.
    Am J Gastroenterol; 2008 Jan 01; 103(1):62-70. PubMed ID: 17894851
    [Abstract] [Full Text] [Related]

  • 16. Treatment of low grade gastric mucosa-associated lymphoid tissue lymphoma in stage I with Helicobacter pylori eradication. Long-term results after sequential histologic and molecular follow-up.
    Montalban C, Santon A, Boixeda D, Redondo C, Alvarez I, Calleja JL, de Argila CM, Bellas C.
    Haematologica; 2001 Jun 01; 86(6):609-17. PubMed ID: 11418369
    [Abstract] [Full Text] [Related]

  • 17. Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy.
    Ueda K, Terui Y, Yokoyama M, Sakajiri S, Nishimura N, Tsuyama N, Takeuchi K, Hatake K.
    Leuk Lymphoma; 2013 Sep 01; 54(9):1928-33. PubMed ID: 23216271
    [Abstract] [Full Text] [Related]

  • 18. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study.
    Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffier B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C.
    J Clin Oncol; 2013 Feb 10; 31(5):565-72. PubMed ID: 23295789
    [Abstract] [Full Text] [Related]

  • 19. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy.
    Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E.
    J Clin Oncol; 2005 Mar 20; 23(9):1979-83. PubMed ID: 15668468
    [Abstract] [Full Text] [Related]

  • 20. Management and long-term follow-up of early stage H. pylori-associated gastric MALT-lymphoma in clinical practice: an Italian, multicentre study.
    Andriani A, Miedico A, Tedeschi L, Patti C, Di Raimondo F, Leone M, Schinocca L, Romanelli A, Bonanno G, Linea C, Giustini M, Hassan C, Cottone M, Zullo A.
    Dig Liver Dis; 2009 Jul 20; 41(7):467-73. PubMed ID: 18945654
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 10.